Hubbry Logo
Dopaminergic pathwaysDopaminergic pathwaysMain
Open search
Dopaminergic pathways
Community hub
Dopaminergic pathways
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Dopaminergic pathways
Dopaminergic pathways
Dopaminergic pathways
View on Wikipedia
from Wikipedia
The main dopaminergic pathways of the human brain

Dopaminergic pathways (dopamine pathways, dopaminergic projections) in the human brain are involved in both physiological and behavioral processes including movement, cognition, executive functions, reward, motivation, and neuroendocrine control.[1] Each pathway is a set of projection neurons, consisting of individual dopaminergic neurons.

There are more than 10 dopaminergic cell groups and pathways. The four major dopaminergic pathways are the mesolimbic pathway, the mesocortical pathway, the nigrostriatal pathway, and the tuberoinfundibular pathway. The mesolimbic pathway and the mesocortical pathway form the mesocorticolimbic system. Two other dopaminergic pathways to be considered are the hypothalamospinal tract and the incertohypothalamic pathway.

Parkinson's disease, attention deficit hyperactivity disorder (ADHD), substance use disorders (addiction), and restless legs syndrome (RLS) can be attributed to dysfunction in specific dopaminergic pathways.

The dopamine neurons of the dopaminergic pathways synthesize and release the neurotransmitter dopamine.[2][3] Enzymes tyrosine hydroxylase and dopa decarboxylase are required for dopamine synthesis.[4] These enzymes are both produced in the cell bodies of dopamine neurons. Dopamine is stored in the cytoplasm and vesicles in axon terminals. Dopamine release from vesicles is triggered by action potential propagation-induced membrane depolarization.[4] The axons of dopamine neurons extend the entire length of their designated pathway.

Pathways

[edit]

Major

[edit]

Six of the dopaminergic pathways are listed below.[5][6][7]

Pathway name Description Associated processes Associated disorders
Mesocorticolimbic
system
Mesolimbic
pathway
 The mesolimbic pathway transmits dopamine from the ventral tegmental area (VTA), which is located in the midbrain, to the ventral striatum, which includes both the nucleus accumbens and olfactory tubercle.[5][6] The "meso" prefix in the word "mesolimbic" refers to the midbrain, or "middle brain", since "meso" means "middle" in Greek.
Mesocortical
pathway
 The mesocortical pathway transmits dopamine from the VTA to the prefrontal cortex. The "meso" prefix in "mesocortical" refers to the VTA, which is located in the midbrain, and "cortical" refers to the cortex.
Nigrostriatal pathway The nigrostriatal pathway transmits dopaminergic neurons from the zona compacta of the substantia nigra[8] to the caudate nucleus and putamen.

The substantia nigra is located in the midbrain, while both the caudate nucleus and putamen are located in the dorsal striatum.

Tuberoinfundibular pathway The tuberoinfundibular pathway transmits dopamine from the hypothalamus to the pituitary gland.

This pathway controls the secretion of certain hormones, including prolactin, from the pituitary gland.[9]

"Infundibular" in the word "tuberoinfundibular" refers to the cup or infundibulum, out of which the pituitary gland develops.

  • regulation of prolactin secretion[10]
Hypothalamospinal tract The hypothalamospinal pathway influences locomotor networks in the brainstem and spinal cord. Modulating motor control and coordination, showcasing the interconnected nature of neural circuits in the brain.
  • motor function.
Incertohypothalamic pathway This pathway from the zona incerta influences the hypothalamus and locomotor centers in the brainstem.
  • visceral and sensorimotor activities.

Minor

[edit]
Hypothalamospinal
Incertohypothalamic
VTA → Hippocampus[6]
VTA → Cingulate cortex[6]
VTA → Olfactory bulb[6]
SNc → Subthalamic nucleus[11]

Function

[edit]

Mesocorticolimbic system

[edit]
The mesocorticolimbic pathway originates through the VTA and passes through the amygdala, nucleus accumbens, and hippocampus. These functions are relative to memory, emotional regulation, motivation, and reward.

The mesocorticolimbic system (mesocorticolimbic circuit) refers to both the mesocortical and mesolimbic pathways.[3][12] Both pathways originate at the ventral tegmental area (VTA) which is located in the midbrain. Through separate connections to the prefrontal cortex (mesocortical) and ventral striatum (mesolimbic), the mesocorticolimbic projection has a significant role in learning, motivation, reward, memory and movement.[13] Dopamine receptor subtypes, D1 and D2 have been shown to have complementary functions in the mesocorticolimbic projection, facilitating learning in response to both positive and negative feedback.[14] Both pathways of the mesocorticolimbic system are associated with ADHD, schizophrenia and addiction.[15][16][17][18]

Mesocortical pathway

[edit]

The mesocortical pathway projects from the ventral tegmental area to the prefrontal cortex (VTA → Prefrontal cortex). This pathway is involved in cognition and the regulation of executive functions (e.g., attention, working memory, inhibitory control, planning, etc.) This intricate neural circuit serves as a crucial communication route within the brain, facilitating the transmission of dopamine, a neurotransmitter associated with reward, motivation, and cognitive control.[19] The prefrontal cortex, being a central hub for executive functions, relies on the input from the mesocortical pathway to modulate and fine-tune cognitive processes essential for goal-directed behavior and decision-making.[20] Dysregulation of the neurons in this pathway has been connected to ADHD.[16]

Mesolimbic pathway

[edit]

Referred to as the reward pathway, mesolimbic pathway projects from the ventral tegmental area to the ventral striatum (VTA → Ventral striatum [nucleus accumbens and olfactory tubercle]).[17] When a reward is anticipated, the firing rate of dopamine neurons in the mesolimbic pathway increases.[21] The mesolimbic pathway is involved with incentive salience, motivation, reinforcement learning, fear and other cognitive processes.[6][16][22] In animal studies, depletion of dopamine in this pathway, or lesions at its site of origin, decrease the extent to which an animal is willing to go to obtain a reward (e.g., the number of lever presses for nicotine or time searching for food).[21] Research is ongoing to determine the role of the mesolimbic pathway in the perception of pleasure.[23][24][25][26]

The nigrostriatal pathway is involved in behaviors relating to movement and motivation.


Nigrostriatal pathway

[edit]

The nigrostriatal pathway is involved in behaviors relating to movement and motivation. The transmission of dopaminergic neurons to the dorsal striatum particularly plays a role in reward and motivation while movement is influenced by the transmission of dopaminergic neurons to the substantia nigra.[27][28] The nigrostriatal pathway is associated with conditions such as Huntington's disease, Parkinson's disease, ADHD, Schizophrenia, and Tourette's Syndrome. Huntington's disease, Parkinson's disease, and Tourette's Syndrome are conditions affected by motor functioning[29] while schizophrenia and ADHD are affected by reward and motivation functioning. This pathway also regulates associated learning such as classical conditioning and operant conditioning.[30]

The tuberoinfundibular pathway transmits dopamine the hypothalamus to the pituitary gland.

Tuberoinfundibular pathway

[edit]

The tuberoinfundibular pathway transmits dopamine from the hypothalamus to the pituitary gland. This neural circuit plays a pivotal role in the regulation of hormonal balance and, specifically, in modulating the secretion of prolactin from the pituitary gland, which is responsible for breast milk production in females. Hyperprolactinemia is an associated condition caused by an excessive amount of prolactin production that is common in pregnant women.[31] After childbirth, the tuberoinfundibular pathway resumes its role in regulating prolactin levels. The decline in estrogen levels postpartum contributes to the restoration of dopaminergic inhibition, preventing sustained hyperprolactinemia in non-pregnant and non-nursing individuals.[32]

Cortico-basal ganglia-thalamo-cortical loop

[edit]

The dopaminergic pathways that project from the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) into the striatum (i.e., the nigrostriatal and mesolimbic pathways, respectively) form one component of a sequence of pathways known as the cortico-basal ganglia-thalamo-cortical loop.[33][34] The nigrostriatal component of the loop consists of the SNc, giving rise to both inhibitory and excitatory pathways that run from the striatum into the globus pallidus, before carrying on to the thalamus, or into the subthalamic nucleus before heading into the thalamus. The dopaminergic neurons in this circuit increase the magnitude of phasic firing in response to positive reward error, that is when the reward exceeds the expected reward. These neurons do not decrease phasic firing during a negative reward prediction (less reward than expected), leading to hypothesis that serotonergic, rather than dopaminergic neurons encode reward loss.[35] Dopamine phasic activity also increases during cues that signal negative events, however dopaminergic neuron stimulation still induces place preference, indicating its main role in evaluating a positive stimulus. From these findings, two hypotheses have developed, as to the role of the basal ganglia and nigrostriatal dopamine circuits in action selection. The first model suggests a "critic" which encodes value, and an actor which encodes responses to stimuli based on perceived value. However, the second model proposes that the actions do not originate in the basal ganglia, and instead originate in the cortex and are selected by the basal ganglia. This model proposes that the direct pathway controls appropriate behavior and the indirect suppresses actions not suitable for the situation. This model proposes that tonic dopaminergic firing increases the activity of the direct pathway, causing a bias towards executing actions faster.[36]

These models of the basal ganglia are thought to be relevant to the study of OCD,[37][38] ADHD, Tourette syndrome, Parkinson's disease, schizophrenia, and addiction. For example, Parkinson's disease is hypothesized to be a result of excessive inhibitory pathway activity, which explains the slow movement and cognitive deficits, while Tourettes is proposed to be a result of excessive excitatory activity resulting in the tics characteristic of Tourettes.[36]

Regulation

[edit]

The ventral tegmental area and substantia nigra pars compacta receive inputs from other neurotransmitters systems, including glutaminergic inputs, GABAergic inputs, cholinergic inputs, and inputs from other monoaminergic nuclei. The VTA contains 5-HT1A receptors that exert a biphasic effects on firing, with low doses of 5-HT1A receptor agonists eliciting an increase in firing rate, and higher doses suppressing activity. The 5-HT2A receptors expressed on dopaminergic neurons increase activity, while 5-HT2C receptors elicit a decrease in activity.[39] The mesolimbic pathway, which projects from the VTA to the nucleus accumbens, is also regulated by muscarinic acetylcholine receptors. In particular, the activation of muscarinic acetylcholine receptor M2 and muscarinic acetylcholine receptor M4 inhibits dopamine release, while muscarinic acetylcholine receptor M1 activation increases dopamine release.[40] GABAergic inputs from the striatum decrease dopaminergic neuronal activity, and glutaminergic inputs from many cortical and subcortical areas increase the firing rate of dopaminergic neurons. Endocannabinoids also appear to have a modulatory effect on dopamine release from neurons that project out of the VTA and SNc.[41] Noradrenergic inputs deriving from the locus coeruleus have excitatory and inhibitory effects on the dopaminergic neurons that project out of the VTA and SNc.[42][43] The excitatory orexinergic inputs to the VTA originate in the lateral hypothalamus and may regulate the baseline firing of VTA dopaminergic neurons.[44][45]

Inputs to the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc)
Neurotransmitter Origin Type of Connection Sources
Glutamate Excitatory projections into the VTA and SNc [42]
GABA Inhibitory projections into the VTA and SNc [42]
Serotonin Modulatory effect, depending on receptor subtype
Produces a biphasic effect on VTA neurons 		[42]
Norepinephrine Modulatory effect, depending on receptor subtype
The excitatory and inhibitory effects of the LC on the VTA and SNc are time-dependent 		[42][43]
Endocannabinoids Excitatory effect on dopaminergic neurons from inhibiting GABAergic inputs
Inhibitory effect on dopaminergic neurons from inhibiting glutamatergic inputs
May interact with orexins via CB1–OX1 receptor heterodimers to regulate neuronal firing 		[41][42][44][46]
Acetylcholine Modulatory effect, depending on receptor subtype [42]
Orexin Excitatory effect on dopaminergic neurons via signaling through orexin receptors (OX1 and OX2)
Increases both tonic and phasic firing of dopaminergic neurons in the VTA
May interact with endocannabinoids via CB1–OX1 receptor heterodimers to regulate neuronal firing 		[44][45][46]

See also

[edit]

Notes

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Dopaminergic pathways

View on Grokipedia
from Grokipedia
Dopaminergic pathways are neural circuits in the that utilize as their primary , originating primarily from clusters of dopaminergic neurons in the and , and projecting to various target regions to modulate essential functions such as , reward and , , and hormone regulation. These pathways are critical for maintaining physiological balance, with dysregulation implicated in disorders including , , addiction, and endocrine disturbances. The four major dopaminergic pathways are well-characterized based on their anatomical origins, projections, and functional roles. The arises from dopaminergic neurons in the pars compacta (A9 cell group) and projects to the dorsal striatum, including the and , where it facilitates voluntary , habit formation, and procedural learning through interactions with the circuits. Degeneration of this pathway, particularly loss of dopaminergic neurons in the , is the hallmark of , leading to motor symptoms like bradykinesia and rigidity. In contrast, the originates from the (VTA; A10 cell group) and extends to limbic structures such as the and , playing a pivotal role in reward processing, motivation, and emotional responses by signaling salience and reinforcing behaviors through phasic release. Hyperactivity in this pathway is associated with addictive behaviors and the positive symptoms of , such as hallucinations and delusions. The , also stemming from the VTA, projects to the and supports higher-order cognitive functions, including , , executive control, and , with modulating cortical excitability via D1 and D2 receptors. Hypofunction here contributes to negative symptoms of , cognitive deficits in attention-deficit/hyperactivity disorder (ADHD), and mood dysregulation in depression. Finally, the tuberoinfundibular pathway (also known as the tuberohypophyseal pathway) originates from dopaminergic neurons in the arcuate nucleus and periventricular nucleus of the hypothalamus (A12 cell group) and projects via the median eminence to the anterior pituitary gland, where it tonically inhibits prolactin secretion through D2 receptor activation, thereby regulating reproductive and lactational processes. Disruption of this pathway, often due to antipsychotic medications blocking D2 receptors, can lead to hyperprolactinemia and associated endocrine side effects. Collectively, these pathways form an interconnected system that integrates sensory, motor, and cognitive information, with acting as a neuromodulator rather than a fast excitatory or inhibitory transmitter, influencing and behavioral adaptability across diverse neural circuits. Advances in and perturbation studies continue to reveal their dynamic interactions, underscoring their therapeutic relevance in neurological and psychiatric conditions.

Overview

Definition and Composition

Dopaminergic pathways refer to neural circuits originating from clusters of dopaminergic neurons primarily located in the and , which project to diverse targets in the , , , cortex, , and , using as the principal to modulate neural activity. These pathways encompass long-range axonal projections that form interconnected networks essential for coordinating brain-wide signaling. For instance, projections from the contribute to circuits like the . The composition of these pathways includes more than ten distinct , classified as A8 through A17 in the foundational proposed by Dahlström and Fuxe based on histochemical fluorescence mapping of catecholamine neurons. The major clusters are situated in the (SNc; A9 group) and (VTA; A10 group) of the , alongside the arcuate nucleus (A12 group) in the ; additional groups such as A8 (retrorubral area), A11 (posterior ), and A13–A15 (diencephalic regions) contribute smaller projections. These neurons, numbering approximately 400,000–600,000 in the , synthesize and release from terminals that often span multiple brain divisions. These pathways hold fundamental importance in orchestrating integrated physiological processes, including , reward processing, cognitive functions, and endocrine regulation, thereby linking sensory inputs with behavioral outputs. Their architecture is evolutionarily conserved across s, from basal chordates like lampreys—where diencephalic neurons project to locomotor regions—to mammals, reflecting ancient origins predating the divergence of major lineages and enabling similar modulatory roles in locomotion and . Key anatomical features of dopaminergic pathways include extensive, often unmyelinated axonal arborizations that enable diffuse over long distances, with as the dominant transmitter but not the sole one in all cases. Subsets of neurons, particularly in the VTA and SNc, co-release alongside glutamate via vesicular glutamate transporter 2 (VGLUT2), influencing excitatory signaling in targets like the , while others incorporate GABA for inhibitory modulation at striatal synapses. Hypothalamic neurons, such as those in the arcuate nucleus, similarly exhibit potential for co-transmission, enhancing their regulatory precision in neuroendocrine contexts.

Dopamine Synthesis and Metabolism

Dopamine biosynthesis occurs in the of neurons and begins with the conversion of L-tyrosine to () by the enzyme (TH), which serves as the rate-limiting step in this pathway. TH requires the cofactor (BH4), along with molecular oxygen and iron, to hydroxylate L-tyrosine at the meta position of its phenolic ring. The subsequent step involves the of to by (AADC), also known as DOPA decarboxylase, which does not require additional cofactors beyond . Following synthesis, dopamine is rapidly sequestered into synaptic vesicles by the (VMAT2), a proton-dependent that exchanges cytoplasmic for protons from the vesicle interior, protecting the from cytosolic degradation. Upon neuronal , these vesicles undergo calcium-dependent , releasing into the synaptic cleft in a process triggered by influx of calcium ions through voltage-gated channels. This release mechanism ensures quantal packaging and controlled expulsion of , with extracellular concentrations in the synaptic cleft typically ranging from basal levels of 10-100 nM to transient peaks of 1-10 μM during burst firing. Dopamine's extracellular lifetime is limited by reuptake into presynaptic neurons via the (DAT), a sodium- and chloride-dependent carrier that facilitates rapid clearance from the . Metabolically, is primarily degraded by two enzymes: (MAO), located on the outer mitochondrial , oxidatively deaminates to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is converted to 3,4-dihydroxyphenylacetic acid (DOPAC) by and then to homovanillic acid (HVA) by ; alternatively, (COMT), an extracellular enzyme, methylates to 3-methoxytyramine (3-MT), which is then converted to HVA by MAO and . These catabolic pathways predominate in different regions, with MAO playing a larger role intracellularly and COMT contributing more to extracellular . The rate of dopamine synthesis is tightly regulated through end-product feedback inhibition, whereby elevated cytoplasmic binds to an allosteric site on TH, reducing its activity and preventing overproduction. This inhibitory mechanism involves both high-affinity and low-affinity -binding sites on TH, allowing fine-tuned control in response to varying neuronal activity levels. Such regulation maintains in levels across , including those in the .

Anatomical Organization

Mesocorticolimbic Pathways

The mesocorticolimbic pathways, comprising the mesolimbic and mesocortical components, originate from dopaminergic neurons clustered in the ventral tegmental area (VTA) of the midbrain, designated as the A10 cell group according to classical histochemical mapping. These pathways form a unified system that conveys dopaminergic signals to limbic and cortical structures, with the mesolimbic pathway projecting primarily to the nucleus accumbens (particularly its core and shell subregions), olfactory tubercle, and basolateral amygdala, resulting in dense innervation of the ventral striatum. In contrast, the mesocortical pathway extends from the VTA to the prefrontal cortex (PFC), targeting areas such as the dorsolateral PFC and orbitofrontal cortex, where terminals exhibit sparser and more diffuse arborizations compared to the compact projections in limbic targets. Shared anatomical features unite these pathways, as both rely on as the principal released from VTA neurons, many of which extend collateral branches to both limbic and cortical destinations, enabling coordinated signaling across the system. Volume transmission, characterized by extrasynaptic diffusion, predominates in certain terminal fields like the PFC and , facilitating broader beyond synaptic clefts. Anatomical variations arise within VTA subregions, where rostral portions preferentially contribute to mesocortical projections to the PFC, while caudal areas more strongly innervate mesolimbic targets such as the and . The VTA receives key afferent inputs from the hippocampus and , which provide and modulation to regulate dopaminergic outflow along these pathways. In vivo visualization of the mesocorticolimbic pathways is achieved through techniques like (PET) and single-photon emission computed tomography (SPECT), employing ligands that bind to the (DAT) or D2 autoreceptors to map projection density and integrity. The , in particular, underpins reward-related signaling within this system.

Nigrostriatal and Tuberoinfundibular Pathways

The originates from neurons in the pars compacta (SNc), corresponding to the A9 in classical mappings of catecholamine systems. These neurons project primarily to the dorsal , encompassing the and , forming a key component of the circuitry. The pathway exhibits topographic organization, with somatopic mapping that aligns medial-lateral axes in the SNc to corresponding striatal regions, enabling precise spatial segregation of motor-related signals. This projection contains an exceptionally high density of , accounting for approximately three-quarters of the brain's total content due to the fine, extensive axonal arborization. The integrates into broader loops, where dopaminergic inputs modulate striatal medium spiny neurons to facilitate coordinated motor output. Anatomical complexity in this pathway is notably enhanced in compared to , featuring more elaborate spiraling projections and greater compartmentalization that support advanced motor refinement. In contrast, the arises from dopaminergic neurons in the arcuate nucleus of the (A12 cell group) and the periventricular region (A14 group), forming short axons that terminate in the and influence the . These neurons release directly into the hypophyseal system, allowing rapid transport to lactotrophs in the pituitary to inhibit secretion. Many tuberoinfundibular neurons co-release with neuropeptides such as , enhancing regulatory signaling in neuroendocrine contexts. This pathway's connectivity is shaped by its proximity to circumventricular organs, including the itself, which lacks a blood-brain barrier and permits humoral influences on hypothalamic release.

Minor and Accessory Pathways

In addition to the major dopaminergic pathways, several minor and accessory projections exist, characterized by smaller populations of neurons and more restricted anatomical distributions. These pathways arise primarily from diencephalic and dopaminergic cell groups, providing sparse innervation to diverse targets including spinal, hypothalamic, and peripheral structures. The hypothalamospinal pathway originates from the in the , particularly within the posterior and , and descends through the lateral funiculus to terminate in the intermediolateral cell column of the . This projection modulates autonomic outflow, influencing sympathetic preganglionic neurons that regulate visceral functions such as cardiovascular control. The incertohypothalamic pathway involves local connections from the A13 dopaminergic group in the to various hypothalamic nuclei, forming a compact network within the . These projections contribute to the integration of sensory and stress-related signals, with terminals identified in regions like the dorsolateral that are implicated in defensive responses. Other minor projections include dopaminergic fibers from the (VTA) extending to the septal nuclei and hippocampus, providing modest input to limbic structures involved in emotional processing, as well as collaterals from (SNc) neurons reaching the subthalamic nucleus, which may fine-tune circuitry. Additionally, sparse dopaminergic elements within the A1 and A2 cell groups of the contribute to projections influencing peripheral targets such as the and , where participates in renal sodium handling and adrenomedullary regulation. These accessory pathways generally comprise smaller neuron populations compared to major systems, often exhibiting mixed neurotransmitter profiles where dopamine coexists with norepinephrine in select cells. Recent advances in mapping, including optogenetic and viral tracing techniques, have confirmed their sparse yet widespread innervation, revealing precise connectivity from diencephalic sources to distant targets like the and .

Physiological Functions

Reward, Motivation, and Addiction

Dopaminergic signaling plays a central role in reward processing through the , which originates in the (VTA) and projects primarily to the (). Dopamine release in this circuit occurs in two main modes: tonic, characterized by steady baseline levels that maintain general arousal and , and phasic, involving brief bursts of dopamine neurons in the VTA that signal salient events. Phasic release, particularly burst firing, encodes reward prediction errors (RPEs), where unexpected rewards elicit strong dopamine surges, while omitted expected rewards cause dips below baseline. This RPE mechanism aligns with the temporal difference (TD) learning model, in which acts as a teaching signal to update predictions about future rewards by comparing actual outcomes to anticipated ones, facilitating associative learning in downstream structures like the . Within the NAc, modulates the balance between D1 and D2 receptor-expressing medium spiny neurons (MSNs) in the shell and core subregions, which differentially influence reward valuation and behavioral output. The NAc shell primarily handles affective aspects of reward, while the core integrates motivational drive with action selection; binding to D1 receptors on MSNs promotes direct pathway activation for reward seeking, whereas D2 receptor stimulation inhibits the indirect pathway, fine-tuning motivational intensity. This D1/D2 balance ensures adaptive responses to rewarding stimuli, with disruptions leading to altered hedonic processing. Dopamine also drives motivation by attributing incentive salience to reward-predictive cues, transforming neutral stimuli into motivators that propel approach behaviors. This process, distinct from hedonic "liking," enhances the "wanting" of rewards through mesolimbic dopamine activation, linking the NAc to the (OFC) for value representation and the (VP) for motor vigor. In the VP, dopamine-modulated neurons amplify cue-triggered motivation, sustaining goal-directed actions even without immediate reward consumption. In addiction, repeated drug exposure sensitizes mesolimbic circuits, amplifying incentive salience for drug cues while diminishing sensitivity to natural rewards. Psychostimulants like induce locomotor and motivational by enhancing release and altering receptor dynamics, leading to compulsive seeking despite adverse consequences. A key mechanism involves downregulation of presynaptic D2 autoreceptors on VTA neurons, which normally inhibit release; this reduction causes tolerance to the drug's euphoric effects by allowing unchecked phasic bursts, perpetuating the addiction cycle. These processes are studied using behavioral paradigms in , such as (CPP), where animals associate a chamber with rewards, revealing 's role in contextual reward learning via NAc activation. Self-administration models further demonstrate motivational drive, as rats actively press levers for intravenous infusions, with blockade in the NAc reducing intake and highlighting circuit-specific contributions to vulnerability.

Motor Control and Movement

The , originating from dopaminergic neurons in the pars compacta and projecting primarily to the dorsal striatum, plays a central role in facilitating voluntary movement through modulation of circuitry. This pathway enables the selection and execution of motor actions by balancing excitatory and inhibitory signals within striatal medium spiny neurons (MSNs). In the , from the differentially influences the direct and indirect pathways to promote or suppress movement. Activation of D1 receptors on MSNs in the direct pathway enhances excitability, leading to inhibition of the internal (GPi) or substantia nigra pars reticulata (SNr), which disinhibits thalamocortical projections and facilitates desired movements. Conversely, activation of D2 receptors on MSNs in the indirect pathway inhibits these neurons, reducing their output to the external globus pallidus (GPe), which in turn decreases excitation of the subthalamic nucleus (STN), reducing GPi/SNr activity and disinhibiting thalamocortical projections to facilitate the execution of desired movements. Striatal thus modulates thalamocortical outputs via these loops involving the and STN, ensuring coordinated . Nigrostriatal dopamine release occurs in distinct firing patterns that support different aspects of motor function. Tonic dopamine, characterized by steady, low-level release from pacemaker firing at approximately 4 Hz, maintains baseline receptor occupancy and sustains posture and ongoing motor stability. In contrast, phasic bursts, involving transient high-frequency spikes (around 20 Hz), transiently elevate dopamine levels to initiate actions, increasing D1 receptor activation and reducing D2 occupancy to bias toward movement execution. Dopamine in the dorsolateral (DLS) is particularly involved in through formation, where repeated actions become automated. Enhanced DLS signaling strengthens in MSNs, promoting the shift from goal-directed to habitual behaviors by encoding consistent motor sequences and contextual cues. Electrophysiological studies using single-unit recordings from neurons reveal their role in action selection. In mice performing motor tasks, approximately 78% of recorded neurons exhibit biphasic firing—increases followed by decreases—correlating with the and switching of actions, predicting behavioral choices with high accuracy (82.7%). These patterns demonstrate how nigrostriatal dynamically biases striatal circuits to select appropriate motor programs.

Cognitive and Executive Processes

Dopaminergic projections from the (VTA) to the (PFC), particularly targeting layers V and VI, play a pivotal role in modulating cognitive and executive processes such as , , and . These mesocortical pathways facilitate the integration of sensory information and sustained neural activity necessary for higher-order functions, with release influencing pyramidal excitability through D1-like receptors. Interactions between dopaminergic and noradrenergic systems in the PFC further refine these processes, as norepinephrine can enhance dopamine's effects on signal-to-noise ratios in cortical circuits, promoting focused . The relationship between dopamine levels and PFC function follows an inverted-U shaped curve, where optimal concentrations enhance and , while deviations impair performance—low levels reduce attentional sustainment, and high levels disrupt focus by overstimulating circuits. D1 receptors, predominantly expressed on dendritic spines of pyramidal neurons, boost excitability and persistent firing critical for maintaining information in tasks. In contrast, D4 receptors contribute to gating mechanisms that filter irrelevant stimuli, helping to suppress distractions and maintain , particularly in conditions like attention-deficit/hyperactivity disorder where D4 hypofunction exacerbates distractibility. Executive functions such as set-shifting and impulse control are supported by 's integration in the (ACC), where it modulates behavioral flexibility and . For instance, D1 receptor activation in the ACC facilitates effort-based and response inhibition, preventing impulsive actions. These roles are evident in paradigms like delay discounting tasks, where PFC levels correlate with preferences for larger delayed rewards over immediate smaller ones, reflecting enhanced . Similarly, performance on the , which assesses set-shifting and , shows an inverted-U relationship with prefrontal D1 receptor binding, underscoring 's tuning of cognitive adaptability.

Endocrine and Homeostatic Regulation

plays a pivotal role in endocrine regulation, particularly through the , where it acts as the primary prolactin-inhibiting factor (PIF) by binding to D2 receptors on lactotroph cells, thereby suppressing synthesis and secretion. This tonic inhibition is essential for maintaining basal levels, with dopamine concentrations in the hypophyseal portal blood directly modulating lactotroph activity via G-protein-coupled D2 receptor signaling that inhibits and reduces intracellular cAMP. Disruption of this pathway, such as in hyperprolactinemia, underscores dopamine's dominance as the key regulator of . In homeostatic , contributes to autonomic balance via the hypothalamospinal pathway, where projections from the A11 nucleus in the posterior provide tonic inhibition to preganglionic sympathetic neurons in the , thereby modulating sympathetic outflow and cardiovascular tone. This descending control helps maintain baseline sympathetic activity, preventing excessive sympathoadrenal responses under normal conditions. Additionally, peripherally synthesized in the acts as a natriuretic , promoting sodium through activation of D1-like receptors on renal tubular , which inhibits sodium-potassium and enhances in response to high sodium intake. This local renal system operates independently of central innervation, with synthesis from circulating regulated by dietary sodium to fine-tune fluid and electrolyte balance. Dopamine also influences circadian rhythms by modulating hypothalamic oscillators, particularly in the (SCN) and arcuate nucleus, where it synchronizes daily oscillations in release and metabolic processes through D2 receptor-mediated interactions with clock genes like Per1 and Per2. This modulation ensures phased alignment of endocrine outputs, such as and , with environmental light-dark cycles, with dopamine release peaking during active phases to reinforce rhythmicity. Feedback loops involving gonadal steroids further regulate dopaminergic activity in the arcuate nucleus, where and testosterone modulate the activity and expression in tuberoinfundibular dopamine (TIDA) neurons, creating a reciprocal interaction that influences reproductive hormone secretion. For instance, enhances turnover in these neurons during the , providing to (GnRH) pulsatility. Peripheral dopamine synthesis extends to non-neuronal tissues, with the producing locally via (AADC) in proximal tubules to regulate sodium handling and , independent of neural input. Similarly, in the gut, enteric neurons and epithelial cells synthesize , accounting for approximately 50% of total body , which locally modulates gastrointestinal , mucosal blood flow, and mucosal integrity through D2-like receptors, contributing to digestive . This peripheral production supports autocrine and paracrine functions without significant contribution to central pools.

Regulatory Mechanisms

Intrinsic Autoregulation

Intrinsic autoregulation in pathways refers to the intrinsic mechanisms that neurons employ to self-regulate signaling and maintain . These processes primarily occur at the presynaptic level and involve feedback loops that adjust synthesis, release, and in response to local concentrations. Key components include autoreceptors, transporters, and vesicular machinery that fine-tune neuronal activity without reliance on external inputs. Presynaptic D2 autoreceptors, located on the somatodendritic regions and terminals of in the (SNc) and (VTA), play a central role in this regulation by inhibiting synthesis and release through Gi/o protein-coupled signaling pathways. Activation of these autoreceptors hyperpolarizes the via G-protein inwardly rectifying (GIRK) channels and reduces voltage-gated calcium influx, thereby suppressing action potential-dependent release. With chronic activity, such as during prolonged stimulation or exposure, D2 autoreceptors undergo desensitization, which diminishes their inhibitory feedback and can lead to enhanced transmission over time. This desensitization involves changes in receptor and internalization, allowing for adaptive responses to sustained endogenous levels. Dopaminergic neurons in the SNc and VTA exhibit intrinsic pacemaker activity, characterized by spontaneous, regular firing at frequencies of 2-5 Hz, which sustains basal tone. D2 autoreceptors mediate pauses in this firing pattern by inducing hyperpolarization in response to somatodendritically released , thereby providing a self-limiting mechanism to prevent excessive excitation. Endogenous also exerts feedback inhibition on (TH), the rate-limiting enzyme in synthesis, primarily through D2 autoreceptor activation that reduces TH phosphorylation and activity, thereby tuning synthesis to match release demands; this process is detailed further in discussions of synthesis and metabolism. The (DAT), expressed on presynaptic terminals, regulates extracellular levels by facilitating into the , with its activity modulated by events that alter transport kinetics and membrane trafficking. by kinases such as (PKC) or (MAPK) can decrease DAT surface expression and efficiency, providing an additional layer of intrinsic control to prevent accumulation. (VMAT2) governs the packaging of into synaptic vesicles, operating as a proton-dependent that exchanges cytosolic for protons, with release probability influenced by vesicular gradients maintained by the vacuolar H+-ATPase. This pH-dependent mechanism ensures efficient loading and quantal release, contributing to the of storage and .

Extrinsic Modulation

Dopaminergic pathways are subject to extrinsic modulation by various neural and hormonal systems, which exert influence through synaptic inputs and circulating factors to fine-tune activity in regions such as the (VTA) and pars compacta (SNc). These modulatory inputs integrate signals from distant brain areas and peripheral sources, enabling adaptive responses to environmental cues, stress, and physiological states. , , serotonergic, , orexinergic, and hormonal mechanisms collectively shape the excitability, firing patterns, and release of neurons, often in a pathway-specific manner. Glutamatergic inputs provide excitatory drive to neurons primarily via ionotropic NMDA and receptors expressed on VTA and SNc somata and dendrites. These receptors facilitate depolarization and burst firing, enhancing release in target areas. Major sources include projections from the (PFC), which convey cognitive and executive signals to the VTA, and the (PPN), which delivers locomotor-related excitation to both VTA and SNc neurons. Activation of these afferents is critical for phasic signaling in reward and motor contexts, as PPN neurons specifically control spike patterning in SNc cells. In contrast, GABAergic inputs impose inhibitory control, often through tonic suppression that limits excessive dopamine release. Local GABAergic interneurons within the VTA and SNc provide direct perisomatic inhibition via GABA_A and GABA_B receptors, dampening dopamine neuron excitability. Additionally, striatal feedback loops, involving GABAergic medium spiny neurons projecting back to the SNc, reinforce this suppression, particularly during ongoing motor activity. These mechanisms maintain balanced dopamine tone in the striatum, preventing overflow that could disrupt motor control. Tonic GABAergic activity is further supported by uptake transporters that sustain extracellular GABA levels, thereby inhibiting dopamine release under baseline conditions. Serotonergic modulation occurs via 5-HT2A and 5-HT2C receptors, which exert opposing effects on release, particularly in mesolimbic reward pathways. The 5-HT2A subtype generally facilitates neuron activity and release in the , promoting reward-seeking behaviors, while 5-HT2C activation inhibits these processes, acting as a brake on . These receptors are expressed on neuron terminals and modulate presynaptic efflux in response to raphe nucleus projections. Such bidirectional control allows serotonin to balance motivational drive, with 5-HT2C antagonism enhancing -mediated locomotion in preclinical models. Orexinergic modulation, mediated by (hypocretin) neurons in the , influences dopaminergic activity primarily through OX1 and OX2 receptors on VTA dopamine neurons. excites these neurons, promoting burst firing and enhancing release in the , which supports , , and reward processing. This modulation integrates with reward circuits and is implicated in and sleep-wake , with recent studies (as of 2025) showing context-dependent effects on anxiety-like behaviors in orexin receptor-deficient models. Hormonal influences further regulate dopaminergic signaling, with and stress-related factors like acting through (CRH). enhances D2 receptor sensitivity and signaling in striatal and mesolimbic regions, increasing dopamine responsiveness and supporting sex-specific behaviors such as . This effect involves rapid non-genomic actions that upregulate D2 receptor function, particularly in females during reproductive cycles. Under stress, CRH released from the activates CRH receptors on VTA dopamine neurons, elevating firing rates and dopamine release to promote adaptive . , downstream of CRH, amplifies this by sensitizing dopamine systems in the ventral , though chronic elevation can lead to dysregulation. Cholinergic inputs, primarily from the PPN and laterodorsal tegmental nucleus, facilitate burst firing of neurons through nicotinic receptors (nAChRs) on VTA and SNc cells. These α4β2 and α7 nAChRs depolarize neurons, promoting phasic bursts that signal salience and reward. Nicotinic activation enhances release in the , underpinning the reinforcing effects of in motivational circuits. This modulation integrates with drive to gate adaptive behaviors.

Development and Plasticity

Embryonic and Postnatal Development

The development of dopaminergic pathways begins in the embryonic stage with the specification of midbrain dopamine (mDA) neurons in the ventral midbrain floor plate, driven by Sonic hedgehog (Shh) signaling and the transcription factor Foxa2, which together induce the expression of key determinants like Lmx1a and Nurr1 for dopaminergic fate. These progenitors arise around embryonic day 8.5 (E8.5) in mice, with initial neurogenesis peaking between E10.5 and E11.5, establishing the foundational populations destined for the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). Genetic factors such as the transcription factors PITX3 and Nurr1 are essential for the survival and differentiation of SNc dopaminergic neurons; Nurr1 (also known as NR4A2) regulates early specification and maintenance, while PITX3 promotes terminal differentiation and protects against apoptosis in a subset of these neurons postnatally. Mutations or deficiencies in these factors lead to selective loss of SNc neurons, highlighting their role in pathway robustness. Following specification, mDA neurons undergo tangential migration from the ventricular zone to their final positions in the VTA and SNc, completing this process by approximately E13 in , guided by cues like and signaling to form the nascent mesostriatal and mesolimbic projections. This migration establishes the basic anatomical framework, with axons beginning to extend toward target regions like the by late embryogenesis. In humans, mDA neuron generation occurs earlier, between 5 and 9 weeks post-conception, with initial functional connectivity emerging by the third trimester as dopaminergic fibers innervate and limbic structures, supporting basic motor and reward-related responses . Postnatally, dopaminergic pathways undergo extensive refinement, with axonal arborization expanding rapidly in during the first few weeks and peaking in density during (around postnatal day 30-60 in rats), particularly in mesocortical projections to the . This maturation coincides with upregulated expression of transporters (DAT) and vesicular monoamine transporter 2 (), which increase progressively from early postnatal stages to , enhancing and vesicular packaging to support heightened signaling demands. In humans, the dopaminergic system matures primarily during adolescence and early adulthood, involving changes in dopamine receptors, presynaptic storage, and connectivity in regions like the striatum and prefrontal cortex; prefrontal dopaminergic projections continue to mature into early adulthood (late teens to mid-20s), with the overall system generally reaching adult-like levels around age 25, though individual variations exist and some habit-related functions may refine further into the 30s. Presynaptic dopamine vesicular storage in the striatum stabilizes around age 18, while D2/D3 receptor availability continues decreasing through adolescence and into early adulthood. Synaptic pruning and myelination refine connectivity for . These changes render the system vulnerable during critical periods; for instance, prenatal alcohol exposure disrupts VTA activity and survival, leading to persistent hypofunction in reward pathways. Sex differences emerge during development, with males showing earlier and more pronounced increases in striatal dopamine receptor density and faster maturation of mesolimbic projections compared to females, influenced by gonadal hormones and potentially contributing to divergent vulnerability profiles. Overall, these embryonic and postnatal processes ensure the progressive assembly of circuits, transitioning from basic functionality in to sophisticated integration in adulthood.

Synaptic Plasticity and Adaptations

Synaptic plasticity in dopaminergic pathways encompasses activity-dependent modifications that strengthen or weaken connections, enabling adaptation to environmental and experiential demands. (LTP) and long-term depression (LTD) at synapses, particularly in the , involve bidirectional trafficking of receptors to postsynaptic sites, which alters synaptic efficacy in response to signaling. This process is modulated by D1 and D2 receptors, where promotes insertion or removal of AMPARs, respectively, supporting reward-related learning. Endocannabinoid signaling further refines these changes by retrogradely inhibiting presynaptic release, thereby gating LTP induction through CB1 receptor on terminals. Adaptations in volume transmission, a non-synaptic mode of dopamine diffusion, allow for broader signaling ranges that adjust based on extracellular dynamics. play a key role via gliotransmission, releasing modulators like that interact with to fine-tune diffusion distances and prevent spillover into adjacent circuits. This glial modulation can extend or restrict dopamine's effective range, adapting to network activity levels and maintaining balanced in regions like the . Experience-dependent plasticity shapes dopaminergic circuits through structural remodeling influenced by environmental factors. enhances dendritic branching in (VTA) neurons, increasing connectivity and responsiveness to novel stimuli. Conversely, triggers dendritic remodeling, such as spine retraction in prefrontal-projecting neurons, which alters motivational drive but can be reversible with stress cessation. At the molecular level, (BDNF) signaling via TrkB receptors promotes neuron survival and synaptic strengthening by activating downstream pathways like PI3K/Akt, which support dendritic growth and resistance to atrophy. Recent studies have revealed a structural continuum in synaptic vesicles, enabling hybrid release modes that blend classical full fusion with partial (kiss-and-run) , allowing flexible output tuned to activity demands. This versatility supports adaptive plasticity without discrete switching between modes.

Pathophysiological Implications

Neurological Disorders

Dopaminergic dysfunction in the is a hallmark of (PD), characterized by progressive degeneration of dopaminergic neurons in the , leading to depletion in the . This degeneration is primarily driven by the accumulation of protein in Lewy bodies, which disrupts neuronal function and promotes cell death. The resulting loss of dopaminergic input imbalances the direct and indirect striatal pathways, with particular impairment in D2 receptor-mediated inhibition of the indirect pathway, contributing to bradykinesia—a core motor symptom marked by slowed movement initiation and execution.30127-1) As detailed in the anatomical organization section, this pathway's vulnerability underscores PD's motor deficits, with neuronal loss exceeding 50% before symptoms manifest. In (HD), alterations in the striatal pathway exhibit a biphasic pattern, beginning with early hypersensitivity and hyperdopaminergia that exacerbates choreiform movements, followed by progressive depletion as medium spiny neurons degenerate. This initial hypersensitivity arises from reduced reuptake and enhanced release in the , leading to overstimulation of postsynaptic receptors before the loss of striatal targets diminishes dopaminergic signaling. The transition to depletion correlates with advanced neuronal loss, contributing to the shift from hyperkinetic to hypokinetic symptoms in later stages. Restless legs syndrome (RLS) involves deficiency in the hypothalamic A11 diencephalospinal pathway, which provides inhibitory modulation to spinal sensory and motor circuits. Reduced release from A11 neurons disrupts this descending control, resulting in sensory disturbances and involuntary movements, particularly during rest. Iron dysregulation further impairs synthesis in this region, amplifying the deficiency. Dystonia features an imbalance in the nigrostriatal pathway's direct and indirect circuits, often with hyperfunction of the direct pathway due to altered modulation in the . This leads to excessive facilitation of thalamic output and reduced inhibition via the indirect pathway, promoting sustained muscle contractions and abnormal postures. or irregular release in the exacerbates the circuit dysfunction, distinguishing primary from other . Therapeutic strategies target these dopaminergic deficits, with L-DOPA serving as the cornerstone for PD by replenishing striatal dopamine levels and alleviating bradykinesia and rigidity. For advanced cases, deep brain stimulation (DBS) of the subthalamic nucleus normalizes basal ganglia hyperactivity, improving motor function with sustained benefits observed up to five years post-implantation. Recent 2025 advancements incorporate , such as nanoparticle-based wireless DBS systems that enable targeted photothermal modulation of aggregates and neuron restoration, enhancing precision and reducing invasiveness.

Psychiatric and Metabolic Disorders

Dopaminergic pathways are implicated in various psychiatric disorders through imbalances in mesolimbic and mesocortical signaling. In schizophrenia, hyperdopaminergia in the mesolimbic pathway contributes to positive symptoms such as hallucinations and delusions, while hypodopaminergia in the mesocortical pathway underlies negative symptoms and cognitive deficits. Recent updates to the dopamine hypothesis, as of 2025, emphasize the interplay between dopaminergic dysregulation and glutamatergic signaling, where disruptions in NMDA receptor function lead to aberrant dopamine release in subcortical regions, exacerbating psychosis. Preclinical models further support this, showing that GABAergic and glutamatergic network disturbances interact with dopaminergic hyperactivity to drive symptom severity. Attention-deficit/hyperactivity disorder (ADHD) involves mesocortical dopaminergic deficits that impair attention and executive function, with reduced availability in prefrontal circuits leading to inattention and . Genetic polymorphisms in the (DAT1) gene are associated with ADHD susceptibility, altering and contributing to lower synaptic levels in attention-related pathways. These variants, particularly the 10-repeat , have been linked to altered left-sided inattention in affected individuals. In addiction, repeated exposure to substances sensitizes the , enhancing release in the and promoting compulsive drug-seeking behavior through incentive sensitization mechanisms. This dysregulation amplifies "wanting" cues associated with rewards, as detailed in reward and functions, while detailed synaptic adaptations are covered elsewhere. Major depressive disorder features ventral tegmental area (VTA) dopaminergic hypofunction contributing to , the diminished ability to experience pleasure from rewarding stimuli. Reduced D1 receptor expression in the further exacerbates motivational deficits, impairing reward processing and decision-making. Optogenetic studies confirm that stimulating VTA dopaminergic neurons can alleviate anhedonia-like behaviors in depressive models. Emerging metabolic roles of dopaminergic signaling extend beyond neuronal functions, particularly in 2025 research highlighting peripheral and glial contributions. In pancreatic beta-cells, dopamine acts via through D2-like receptors to inhibit insulin secretion, modulating glucose and potentially linking dopaminergic dysregulation to risk. Astrocytic signaling in the influences by modulating behavioral flexibility and whole-body , where high-fat diets alter astrocyte structure and dopamine-dependent reward processing, promoting overeating. Dopaminergic decline in , observed in pathways, contributes to cognitive and motivational impairments, with degeneration of VTA neurons exacerbating amyloid-beta pathology and synaptic loss. Non-neuronal dopaminergic effects include immune modulation via D5 receptors on T-cells, where dopamine binding enhances T-cell activation and production, such as IL-10 and TNFα, influencing adaptive immunity. D5 signaling plays a dual role in , potentiating Th17 responses while favoring regulatory T-cell suppression in experimental models.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10778701/
  2. https://www.nature.com/articles/s41398-022-02233-0
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3479149/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816693/
  5. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2011.00021/full
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5096020/
  7. https://www.pnas.org/doi/10.1073/pnas.1600684113
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3250102/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC11089423/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3065393/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4338835/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5028832/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6629510/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC6842680/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4956566/
  16. https://biosignaling.biomedcentral.com/articles/10.1186/1478-811X-11-34
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2630537/
  18. https://pubmed.ncbi.nlm.nih.gov/18513370/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC11011984/
  20. https://www.sciencedirect.com/topics/neuroscience/mesolimbic-pathway
  21. https://www.sciencedirect.com/topics/neuroscience/mesocortical-pathway
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4436899/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6347508/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC1913185/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3705195/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC3543080/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3014656/
  28. https://www.sciencedirect.com/topics/neuroscience/nigrostriatal-pathway
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6772499/
  30. https://www.sciencedirect.com/topics/medicine-and-dentistry/hypophysis-hormone
  31. https://www.sciencedirect.com/science/article/pii/S0920996498001583
  32. https://www.sciencedirect.com/science/article/pii/0006899383909782
  33. https://www.ncbi.nlm.nih.gov/books/NBK279126/
  34. https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/dopaminergic-cell-groups
  35. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2013.00041/full
  36. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013306
  37. https://www.nature.com/articles/s41598-018-25908-5
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6404492/
  39. https://www.sciencedirect.com/science/article/pii/0006899375901316
  40. https://pubmed.ncbi.nlm.nih.gov/6493444/
  41. https://www.sciencedirect.com/science/article/pii/S0006899399024737
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4522312/
  43. https://www.frontiersin.org/journals/neuroanatomy/articles/10.3389/fnana.2020.00013/full
  44. https://onlinelibrary.wiley.com/doi/abs/10.1002/cne.902330303
  45. https://www.pnas.org/doi/10.1073/pnas.1312414110
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8992377/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC5549862/
  48. https://www.jneurosci.org/content/16/5/1936
  49. https://www.nature.com/articles/s41380-019-0484-3
  50. https://pubmed.ncbi.nlm.nih.gov/17072591/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC2606924/
  52. https://www.sciencedirect.com/science/article/pii/S0896627300810569
  53. https://www.nature.com/articles/npp201430
  54. https://www.ncbi.nlm.nih.gov/books/NBK5229/
  55. https://doi.org/10.1016/j.neuron.2012.09.023
  56. https://doi.org/10.1523/JNEUROSCI.20-24-08987.2000
  57. https://doi.org/10.1523/JNEUROSCI.04-11-02866.1984
  58. https://doi.org/10.1523/JNEUROSCI.04-11-02877.1984
  59. https://doi.org/10.1016/j.neuron.2017.02.029
  60. https://doi.org/10.1038/nature11846
  61. https://www.jneurosci.org/content/jneuro/16/5/1922.full.pdf
  62. https://www.pnas.org/doi/10.1073/pnas.98.1.301
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC4879059/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3111448/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC2170853/
  66. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2014.00183/full
  67. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2013.00062/full
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC1783632/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC4289950/
  70. https://www.jneurosci.org/content/28/46/12032
  71. https://pubmed.ncbi.nlm.nih.gov/18477617/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC2276716/
  73. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00768/full
  74. https://psychiatryonline.org/doi/10.1176/ajp.156.2.169
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC4419129/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6342207/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC5376559/
  78. https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2022.957193/full
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC2883625/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6493904/
  81. https://www.ahajournals.org/doi/10.1161/hy0901.096422
  82. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1098412/full
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC8962300/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC6793718/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC5643088/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC6363932/
  87. https://www.nature.com/articles/s41467-020-18247-5
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC4279075/
  89. https://www.nature.com/articles/npp200929
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC8059491/
  91. https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2012.00054/full
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC8048738/
  93. https://www.science.org/doi/10.1126/science.7189902
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC2465205/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7470928/
  96. https://www.cell.com/neuron/fulltext/S0896-6273%2806%2900373-4
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC2788512/
  98. https://www.sciencedirect.com/science/article/abs/pii/S0014488604002213
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2872921/
  100. https://journals.biologists.com/dev/article/130/11/2535/41944/Pitx3-is-required-for-motor-activity-and-for
  101. https://www.nature.com/articles/s41419-021-04319-x
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC3015042/
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC10114107/
  104. https://journals.biologists.com/dev/article/149/23/dev200504/285890/Single-cell-transcriptional-and-functional
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC2845533/
  106. https://pubmed.ncbi.nlm.nih.gov/30697146/
  107. https://www.nature.com/articles/s41467-020-14693-3
  108. https://www.jneurosci.org/content/37/45/10855
  109. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14901
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC8469878/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC6508969/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC3552338/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC3176941/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC9700696/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC7554522/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC10189610/
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC6758130/
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC7019526/
  119. https://www.sciencedirect.com/science/article/pii/S0166223625001973
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC7191035/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC3281589/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC3221774/
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC3701870/
  124. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2017.00171/full
  125. https://karger.com/ene/article/66/1/18/134398/Possible-Sites-of-Therapeutic-Action-in-Restless
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC5841143/
  127. https://www.sciencedirect.com/science/article/pii/S0301008219301029
  128. https://www.ncbi.nlm.nih.gov/books/NBK482140/
  129. https://jamanetwork.com/journals/jamaneurology/fullarticle/2838886
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC11734722/
  131. https://www.nature.com/articles/s41380-025-03229-0
  132. https://www.researchgate.net/publication/270909628_Glutamate_and_dopamine_in_schizophrenia_An_update_for_the_21st_century
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC11604610/
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC3513209/
  135. https://www.nature.com/articles/1300839
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC5171207/
  137. https://www.annualreviews.org/doi/10.1146/annurev-psych-010418-103337
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC5716179/
  139. https://behavioralandbrainfunctions.biomedcentral.com/articles/10.1186/s12993-025-00269-y
  140. https://onlinelibrary.wiley.com/doi/full/10.1002/jnr.25014
  141. https://www.sciencedirect.com/science/article/pii/S0303720724001503
  142. https://www.nature.com/articles/s41467-025-60968-y
  143. https://pmc.ncbi.nlm.nih.gov/articles/PMC12417303/
  144. https://pubmed.ncbi.nlm.nih.gov/23701196/
  145. https://pmc.ncbi.nlm.nih.gov/articles/PMC6048279/
Add your contribution
Related Hubs
User Avatar
No comments yet.